Psoriasis clinical trials at UCSF

5 in progress, 3 open to eligible people

Psoriasis is an immune-related skin disease that causes red, scaly plaques. UCSF is looking at skin and blood immune cells before and after use of deucravacitinib, a TYK2 inhibitor. UCSF is also studying immune gene patterns and the effects of an IL-23 blocker on scalp lesions.

Showing trials for

  • Correction of Psoriatic T Cell Signatures by Deucravacitinib

    open to eligible people ages 18-75

    This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

    San Francisco, California

  • Guselkumab Immunogenetics

    open to eligible people ages 18 years and up

    This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.

    San Francisco, California

  • Immune Spatial Features of Guselkumab Cutaneous Response

    open to eligible people ages 18 years and up

    This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

    San Francisco, California

  • JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

    Sorry, in progress, not accepting new patients

    The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

    Fresno, California and other locations

  • Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

    Sorry, not yet accepting patients

    This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

    San Francisco, California

Our lead scientists for Psoriasis research studies include .

Last updated: